Insurance Coverage For Ozempic, Zepbound Went Down In 2025 [Forbes]
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: Forbes
for many of them. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images This could end up making your wallet lighter if you are taking Ozempic or Zepbound for diabetes or weight loss. From 2024 to 2025, insurance coverage of Ozempic, which contains semaglutide, went down by 22%, That meant an additional 1.1 million people no longer had such coverage for the most often filled glucagon-like peptide-1 receptor agonist. During that same time span, the number of people with no insurance coverage for another GLP-1 receptor agonist, Zepbound, increased by 14%, which meant that another 4.9 million or so more people were bound for no insurance coverage for the tirzepatide-containing Zepbound. Demand For Ozempic, Zepbound And Other GLP-1 Agonists Continues To Increase Despite Prices So, insurance coverage for these medications has gone down while demand for them has continued to go up and up. of data from a nationally-represent
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- GoodRx (NASDAQ:GDRX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GoodRx (NASDAQ:GDRX) was given a new $4.00 price target on by analysts at Morgan Stanley.MarketBeat
- GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Former Steelers QB struggles in his first start with new team [USA TODAY]USA TODAY
- Smart ways to spend your remaining FSA money before year-end deadline [CBS News]CBS News
GDRX
Earnings
- 11/4/25 - Beat
GDRX
Sec Filings
- 12/12/25 - Form 8-K
- 12/8/25 - Form 4
- 12/8/25 - Form 3/A
- GDRX's page on the SEC website